Ryvu Therapeutics announced presentations of preclinical data from the PRMT5 program and synthetic lethality platform, as well as preclinical data on MEN1703 in B-cell lymphomas, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place in Boston, Massachusetts.
